RBC Capital analyst Arun Viswanathan lowered his price target on Albemarle to $83 to reflect the "ample near-term lithium supply", citing the company's recent decision to suspend part of its lithium conversion expansion plans due to to higher than expected industry inventory levels. The analyst is keeping his Outperform rating on the stock however with a positive view on its "responsible" capital expenditure decisions and its "leadership role" to limit the lithium supply overbuild. Viswanathan also sees Albemarle as "well-diversified" with its technology, which could "provide an advantage" relative to lithium producers that took larger battery chemistry bets.